PamelaSueBeckerMDPhD(She/Her)

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Professor

Overview of Dr. Becker

Pamela S. Becker, MD, PhD is a physician scientist at City of Hope in the Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation.
Her research studies include the mechanism of cell adhesion-mediated chemotherapy resistance in AML, hematopoietic stem cell gene therapy for an inherited disorder of DNA repair, and precision therapy for AML, multiple myeloma, CML and all hematologic malignancies based on high-throughput drug sensitivity testing including correlation of mutations and gene expression with drug sensitivity.
Becker earned a medical degree and PhD at Harvard Medical School in the Harvard-MIT Health Sciences and Technology Program in Boston. She completed an internal medicine internship and residency at Beth Israel Hospital/Harvard Medical School in Boston and a fellowship in hematology at Yale University School of Medicine.
She has a long career as a translational researcher and is an author on over 200 peer-reviewed and other publications in the fields of inherited blood disorders, hematologic malignancies, and hematopoietic cell transplantation.

Office
City of Hope
1500 E. Duarte Rd
Duarte, CA 91010
Book by Phone+1(661) 446-8179

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1986 - 1988
Harvard Medical SchoolClass of 1986

Certifications & Licensure

WA State Medical License 2003 - 2026
CA State Medical License 2019 - 2025
MA State Medical License 1993 - 2005
CT State Medical License 1988 - 2003
American Board of Internal Medicine Hematology

Clinical Trials

Gene Therapy for Fanconi Anemia Start of enrollment: 2012 Feb 22
Terminated
Phase 1
Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Start of enrollment: 2013 May 21
Completed
Not Applicable
Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay Start of enrollment: 2013 Aug 02
Completed
Not Applicable
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML Start of enrollment: 2014 Feb 01
Completed
Phase 1
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm Start of enrollment: 2014 Jun 01
Completed
Not Applicable
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy Start of enrollment: 2020 Jan 15
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

8 citations
Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid
Keith R. Loeb, Sindhu Cherian, Pamela S. Becker, Roland B. Walter, John M. Pagel
British Journal of Haematology. 2016-01-01
132 citations
A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia
Su-In Lee, Safiye Celik, Benjamin A. Logsdon, Scott M. Lundberg, Timothy J. Martins
Nature Communications. 2018-01-03
38 citations
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Amer M. Zeidan, Maya Ridinger, Tara L. Lin, Pamela S. Becker, Gary J. Schiller
Clinical Cancer Research. 2020-09-30

Journal Articles

Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, Mitoxantrone, and G-CSF with Dose-Escalated Mitoxantrone for relapsed/refractory Acute Myeloid Leukemia or Other H...
Kelda M Gardner, Vivian G Oehler, Heather A Smith, Anna B Halpern, Paul C Hendrie, Sarah A Buckley, Roland B Walter, Pamela S Becker, Ryan D Cassaday, Asma Anwar, Bart..., Haematologica
Long Term Follow-up of Tandem Autologous-Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma
Parameswaran Hari, Brenda M Sandmaier, Pamela S Becker, Leona Holmberg, Damian J Green, Peter A McSweeney, David G Maloney, Thomas R Chauncey, Haematologica
Novel Lineage Depletion Preserves Autologous Blood Stem Cells for Gene Therapy of Fanconi Anemia Complementation Group A
Lauri M Burroughs, Pamela S Becker, Haematologica

Abstracts/Posters

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting
Pamela S. Becker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based TherapiesClinically Relevant Abstract
Pamela S. Becker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...
Pamela S. Becker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Othe...
Pamela S. Becker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Pamela S. Becker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Machine Learning in Hematology
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lympho...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
From Bone Marrow to Mobilized Peripheral Blood Stem Cells: The Circuitous Path to Clinical Gene Therapy for Fanconi AnemiaClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
High Throughput Drug Screening of Leukemia Stem Cells Reveals Resistance to Standard Therapies and Sensitivity to Other Agents in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Comprehensive Board Review in Hematology and Medical Oncology 2013
The University of Texas, M. D. Anderson Cancer Center, Houston, Texas - 9/23/2013
A Comprehensive Board Review in Hematology and Medical Oncology 2012
The University of Texas, M. D. Anderson Cancer Center, Houston, Texas - 9/10/2012
Join now to see all

Press Mentions

BBI ‘Catalytic Collaboration’ Grant Leads to ‘Extraordinary’ Progress in Research for Directing Treatment of Multiple Myeloma PatientsMay 28th, 2021

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois Blue Advantage HMO
BCBS Illinois BlueChoice Select
BCBS Illinois HMO
BCBS Illinois PPO
BCBS North Carolina BlueOptions PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Health Care PPO Platinum
Coventry Missouri - HMO/POS
First Choice
First Health PPO
Great West PPO
Health Alliance PPO
HealthLink PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
ODS Network
Premera BCBS Heritage & Heritage Plus 1
Providence Health System Personal Option
Regence Washington - Preferred Provider Network
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment